Galapagos announces planned retirement of CEO
August 30 2021 - 4:01PM
Mechelen, Belgium; 30 August 2021, 22.01 CET;
regulated information – Galapagos NV (Euronext & NASDAQ: GLPG)
announces the planned retirement of CEO Onno van de Stolpe.
Onno van de Stolpe co-founded Galapagos in 1999
and built and led the company as CEO from its early R&D days
through to the commercial launch of Jyseleca® (filgotinib) in
Europe. Onno will retire and make way for a new CEO to lead the
company going forward; he plans to stay on as CEO until a successor
is appointed. The Supervisory Board has initiated an external
search for his replacement.
“Over the last 20 years, Onno has built one of
the most important biotechnology companies in Europe, guiding it
from a new start-up to a public company that recently launched its
first approved medicine. The Supervisory Board is deeply grateful
to Onno for his years of dedication and leadership, and for
creating an enduring organization,” said Dr. Raj Parekh, Chairman
of the Supervisory Board of Galapagos.
“My time at the helm of Galapagos will come to
an end. We have built a great company that bridges novel target
discovery all the way to new medicines in the clinic and to the
patient. Despite recent setbacks, we continue to progress a deep
pipeline of novel target-based compounds, while the commercial
roll-out of our first approved product is underway. With our strong
balance sheet and long-term R&D collaboration with Gilead, I am
confident that the company is well positioned to grow again from
here,” said Onno van de Stolpe, CEO.
About Galapagos
Galapagos NV discovers and develops small
molecule medicines with novel modes of action, several of which
show promising patient results and are currently in development in
multiple diseases. Our pipeline comprises discovery through Phase 3
programs in inflammation, fibrosis and other indications. Our
ambition is to become a leading global biopharmaceutical company
focused on the discovery, development, and commercialization of
innovative medicines. More information at www.glpg.com.
This press release contains inside information
within the meaning of Regulation (EU) No 596/2014 of the European
Parliament and of the Council of 16 April 2014 on market abuse
(market abuse regulation).
Except for filgotinib’s approval for the
treatment of rheumatoid arthritis by the European Commission, Great
Britain’s Medicines and Healthcare products Regulatory Agency and
Japanese Ministry of Health, Labour and Welfare, our drug
candidates are investigational; their efficacy and safety have not
been fully evaluated by any regulatory authority.
Jyseleca® is a trademark of Galapagos NV and Gilead Sciences,
Inc. or its related companies.
Contact
Investors:Elizabeth GoodwinVP Investor Relations +1 781
460 1784
Sofie Van GijselSenior Director Investor Relations+1 781 296
1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63ir@glpg.com
Media:
Carmen Vroonen Global Head of
Communications and Public Affairs +32 473 82 48
74
Evelyn FoxDirector Executive Communications+31 6
53 59 19 99communications@glpg.com
Forward-looking statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks,
uncertainties and other factors that could cause actual results to
differ materially from those referred to in the forward-looking
statements and, therefore, the reader should not place undue
reliance on them. These risks, uncertainties and other factors
include, without limitation, the inherent risks associated with
clinical trial and product development activities, competitive
developments, and regulatory approval requirements, including the
risk that data from the ongoing and planned clinical research
programs in rheumatoid arthritis, Crohn’s disease, ulcerative
colitis, idiopathic pulmonary fibrosis, osteoarthritis, and other
inflammatory indications may not support registration or further
development due to safety, efficacy or other reasons, the timing or
likelihood of regulatory authorities approval of marketing
authorization for filgotinib for RA, UC or any other indication,
such regulatory authorities requiring additional studies, changes
in our management board and key personnel, our ability to
effectively transfer knowledge during this period of transition,
the search and recruitment of a suitable successor to lead our
organization, the risk that Galapagos will be unable to
successfully achieve the anticipated benefits from its leadership
transition plan, the possibility that Galapagos will encounter
challenges retaining or attracting talent, the risk that Galapagos
will not be able to continue to execute on its business plan,
Galapagos’ strategic R&D ambitions, including progress on our
fibrosis portfolio, and potential changes of such ambitions,
Galapagos’ reliance on collaborations with third parties, including
the collaboration with Gilead for filgotinib, the uncertainty
regarding estimates of the commercial potential of filgotinib, the
timing of and the risks related to implementing the amendment of
our arrangement with Gilead for the commercialization and
development of Jyseleca (filgotinib), the uncertainties relating to
the impact of the COVID-19 pandemic and our strategy, business
plans and focus, as well as those risks and uncertainties
identified in our Annual Report on Form 20-F for the year ended 31
December 2020 and our subsequent filings with the SEC. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. The
forward-looking statements contained herein are based on
management’s current expectations and beliefs and speak only as of
the date hereof, and Galapagos makes no commitment to update or
publicly release any revisions to forward-looking statements in
order to reflect new information or subsequent events,
circumstances or changes in expectations.
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024